Precigen Shares Surge 52.5% as Papzimeos Sales Reach $74.6 Million

Zacks Investment Research··USEU·Read original
3▲1 ▼1Impact / 5
Summary · why it matters

Precigen shares have climbed 52.5% over the past three months, outpacing a 0.2% decline for the industry, on the strength of its sole marketed drug, Papzimeos. Papzimeos, the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis, generated $74.6 million in revenue in the first six months of 2026, with second-quarter product sales more than doubling sequentially. A marketing authorization application for Papzimeos in adults with recurrent respiratory papillomatosis is under review in Europe, and the drug holds seven years of FDA market exclusivity through Aug. 14, 2032. Inovio Pharmaceuticals is developing INO-3107 as a competing treatment for recurrent respiratory papillomatosis, with an FDA decision expected on Oct. 30, 2026. Beyond Papzimeos, Precigen is developing PRGN-2009 through its AdenoVerse platform, which recently received FDA platform technology designation, and a phase II study is testing PRGN-2009 with Merck's Keytruda in recurrent or metastatic cervical cancer, with a portfolio update planned by the end of 2026.

Impact on assets 4

Biotech & Genomic Medicine± Mixed · 3 stocks
Precigen Inc
PGEN
▲ PositiveDemandrelevance

Papzimeos generated $74.6 million in first-half 2026 revenue with Q2 sales more than doubling sequentially.

Inovio Pharmaceuticals Inc
INO
▼ NegativeCompetitionrelevance

Inovio's competing RRP treatment INO-3107 faces an FDA decision Oct 30, 2026, while Precigen's Papzimeos already holds approval and seven years of exclusivity.

Critical Materials & Supply Chain▲ · 1 stocks
© 2026 MarketIVNews